The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study
In this retrospective study we reviewed the clinical course of every patient with multiple myeloma treated from 2006 to 2016 at Vejle Hospital: 303 patients with a median age of 69 years at diagnosis received a median of four (range 1–18) lines of therapy; 149 in a 2006–2010 cohort and 154 in a 2011...
Main Authors: | Agoston Gyula Szabo, Katrine Fladeland Iversen, Sören Möller, Torben Plesner |
---|---|
Format: | Article |
Language: | English |
Published: |
SAABRON PRESS
2019-08-01
|
Series: | Clinical Hematology International |
Subjects: | |
Online Access: | https://www.atlantis-press.com/article/125914915/view |
Similar Items
-
The Incidence and Timing of Blood Cultures in Multiple Myeloma – Results from a Retrospective, Single Center, Real-World Study
by: Agoston Gyula Szabo, et al.
Published: (2020-08-01) -
Nationwide implementation of lenalidomide maintenance in multiple myeloma: A retrospective, real‐world study
by: Mads Harsløf, et al.
Published: (2024-04-01) -
High Expression of the Costimulatory Checkpoint Factor DNAM-1 by CD4+ T-Cells from Multiple Myeloma Patients Refractory to Daratumumab-Containing Regimens
by: Katrine Fladeland Iversen, et al.
Published: (2022-08-01) -
The real‐world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies
by: Agoston Gyula Szabo, et al.
Published: (2023-11-01) -
Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
by: Kristian T. Andersen, et al.
Published: (2020-01-01)